SecBot SecBot
8-K ·Filed Jun 8, 2026

CELC

Celcuity Inc.
MIXED
Impact 6/10
Horizonweeks Processed5mo ago SEC0001493152-26-027717
8-K material event: Items 1.01, 1.02
Actionable Insight ◆ Mixed

The debt-for-debt refinancing (secured to unsecured) and extended cash runway through 2028 are credit-positive for preferred holders. Monitor the stock price relative to the $124.53 conversion threshold, sustained trading above may trigger conversion and dilute common equity, which would be neutral for the preferred. The large total convertible balance (~$701M) could pressure the common if the stock rallies significantly, but preferred dividend coverage improves with the term loan repayment.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$92.59
T+0 close · Jun 8, 2026 · via day close
Latest settled
+3.90%
T+60 · $96.20
Vs SPY
+0.09%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 9 $92.59entry
  2. T+1 · 5mo ago −4.70%α −3.12% · $88.24
  3. T+5 · 5mo ago −4.70%α −7.11% · $88.24
  4. T+20 · 4mo ago +24.98%α +23.53% · $115.72
  5. T+60 · 3mo ago +3.90%α +0.09% · $96.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Celcuity closed a $500M (plus $75M over-allotment) 0.250% convertible senior notes offering on June 8, 2026, executing the second supplemental indenture and underwriting agreement filed as exhibits to this 8-K. Net proceeds of ~$484.3M will repay the $137.9M secured term loan (de-levering to zero secured debt) and fund working capital, commercial launch, and pipeline through 2028. This follows preliminary filings from June 3 and June 5; the combination of large unsecured convert issuance (~$701M in total converts including prior tranches) with secured debt repayment is credit-positive for the capital structure but adds substantial leverage and potential dilution.

Key Facts

  • $575M total (initial $500M + $75M over-allotment) of 0.250% convertible senior notes due 2032 issued
  • Initial conversion rate of 8.0302 shares per $1,000 principal, equal to ~$124.53 conversion price
  • Initial conversion premium was 57.2% above the $79.23 stock price (based on preliminary pricing; final terms confirmed in indenture)
  • Net proceeds of ~$484.3M will fully repay the $137.9M secured term loan and fund clinical/commercial pipeline
  • The de-levering to $0 secured debt is a significant credit event for the preferred equity structure
  • Aggregate convertible debt now totals ~$701M ($201M prior + $575M new), adding material leverage and potential stock dilution
  • Underwriters purchased at 97.0% of principal; Jefferies, J.P. Morgan, TD Cowen, Guggenheim led the syndicate

Financial Impact

Deleveraging of $137.9M secured term loan (~$484.3M net proceeds) is positive credit event, but raises total convertible debt to ~$701M (potential for substantial dilution if converted; initial conversion rate implies 4.62M shares on base of ~28M outstanding at the $124.53 conversion price plus make-whole adjustments up to 11.2422 shares per $1,000 = ~6.46M shares fully diluted).

debtdilutioncapital_structurecash_runway

Risk Factors

  • ~$701M in total convertible debt creates significant potential common stock dilution if conversion threshold is met
  • Reliance on capital markets for future financing needs; large unsecured convert exposes balance sheet to conversion risk
  • Execution risk in commercial launch and pipeline development given funds deployment timeline

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-027717
Exhibit: ex1-1.htm0001493152-26-027717

Track record

26 reports on CELC

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 9 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
  3. Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
  7. Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
  8. Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
  9. Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
  10. Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 8h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 8, 2026